# Edwards Lifesciences: how the business works

> For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Edwards Lifesciences Corporation · NYSE: EW · Sector: Health Care

Updated for Q3 FY2026 · checked Nov 20, 2026

This is the plain-text version of https://cityfort.co/stocks/edwards-lifesciences. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Edwards Lifesciences: how the business works", with the page URL.

## The 30-second summary

Edwards Lifesciences makes replacement heart valves and valve repair systems, and had net sales of $6.07 billion and net income of $1.07 billion in FY2025. TAVR aortic valves, fitted through a catheter, were 74% of sales, and customers in the United States 58.4%. In the first nine months of 2026 TMTT sales grew 47.7% and TAVR sales 11.1%, while Q3 FY2026 included a $220.2 million impairment.

## 5 points

- **What it sells:** Edwards Lifesciences sells replacement heart valves and valve repair systems: TAVR aortic valves brought in $4.49 billion of FY2025 net sales of $6.07 billion, surgical valves $1.03 billion and TMTT mitral and tricuspid devices $550.6 million. [S4]
- **Who pays it:** Hospitals and their heart teams pay Edwards: customers in the United States were 58.4% of FY2025 net sales and customers outside the United States 41.6%. [S4]
- **What it keeps from $100:** Of every $100 that came in during FY2025, Edwards kept $16.9 as net income from continuing operations, including interest income on its cash and a $146.9 million impairment loss; FY2025 operating income was $1.26 billion. [S4]
- **Where the operating profit comes from:** Edwards reports profit by region: the United States earned $2.35 billion of FY2025 segment profit and Europe $796 million, before $2.03 billion of corporate costs not assigned to regions. [S4]
- **The one thing to watch:** TAVR sales grew 8.0% in Q3 FY2026, against 11.1% for the first nine months of 2026, and on Nov 4, 2026 Edwards guided to 2026 TAVR growth of 9.0% to 9.5%. [S14, S1]

## What does Edwards Lifesciences sell?

Edwards makes replacement heart valves and devices that repair or replace leaking heart valves. Most sales come from aortic valves delivered through a catheter, a thin tube passed through a blood vessel. The heart keeps beating during the procedure.

- **TAVR: SAPIEN aortic valves:** Transcatheter aortic valve replacement for patients with severe aortic stenosis, a narrowed aortic valve. Sales were $4.49 billion in FY2025, 74% of the total. [S4]
- **TMTT: PASCAL, EVOQUE and SAPIEN M3:** Catheter systems that repair or replace the mitral and tricuspid valves. Sales were $550.6 million in FY2025, 9% of the total, up 56.4% on FY2024. [S4]
- **Surgical: INSPIRIS, MITRIS and KONECT RESILIA:** Tissue heart valves that surgeons implant during open-heart operations. Sales were $1.03 billion in FY2025, 17% of the total. [S4]

## Who pays Edwards Lifesciences?

- **Customers in the United States (58.4% of revenue):** Hospitals and their heart teams, served almost entirely by Edwards’ own sales forces. They were 58% of FY2025 net sales. [S4]
- **Customers outside the United States (41.6% of revenue):** Sold in about 100 countries through direct sales forces and independent distributors, often on consignment (stock kept at the hospital until used). Europe was 60% of these sales, Japan 14% and the rest of the world 26%. [S4]
- **Customer concentration:** No single customer accounted for 10% or more of Edwards’ net sales in FY2025, according to the FY2025 10-K. [S4]

## Where the money went (FY2025)

1. Edwards sold $6.07 billion of heart valves and valve repair systems in FY2025 and earned $168.8 million of interest on its cash.
2. Making the products cost $1.33 billion, leaving $4.73 billion of gross profit.
3. Selling and administration took $2.09 billion and research $1.08 billion; patent and litigation costs added $325.4 million.
4. A $146.9 million impairment loss below operating income and $216.9 million of income tax left $1.06 billion from continuing operations.
5. Adding $13.4 million from businesses already sold and $4.1 million of minority holders’ losses gives Edwards $1.07 billion of net income.

Sources: S4.

## Key numbers by year (US$ million)

Financials: consolidated, US$ million. Fiscal years are the company's own: Fiscal year ends Dec 31 (the calendar year). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (US$ per share, diluted) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY2021 (As first reported, incl. Critical Care) | 5,232.5 | 1,825.1 | 34.9% | 1,503.1 | 28.7% | 2.38 | 1,732.1 | 325.8 | 1,406.3 | S25 |
| FY2022 (restated) | 4,464 | 1,638 | 36.7% | 1,521.9 | 34.1% | 2.44 | 1,218.2 | 244.6 | 973.6 | S8, S25 |
| FY2023 (restated) | 5,010 | 1,453.8 | 29.0% | 1,402.4 | 28.0% | 2.3 | 895.8 | 253 | 642.8 | S4, S12 |
| FY2024 | 5,439.5 | 1,533.9 | 28.2% | 4,174.6 | 76.7% | 6.97 | 542.3 | 252.4 | 289.9 | S8 |
| FY2025 | 6,067.6 | 1,420.8 | 23.4% | 1,073.5 | 17.7% | 1.83 | 1,595.2 | 260.2 | 1,335 | S4 |

- EBITDA here = operating income plus depreciation and amortization (from the cash flow statement).
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of Sep 30, 2026, US$ million)

At Sep 30, 2026, cash and short-term investments of $4.64 billion were more than seven times Edwards’ only debt, a $600 million note. [S1, S4]

| Item | Value |
| --- | --- |
| Total debt | 598.8 |
| Cash and investments | 4,644.7 |
| Net debt (debt minus cash) | −4,045.9 |
| Net worth (shareholders' money) | 10,861.1 |
| Debt to equity (times) | 0.06 |

- Net cash of $4.05 billion = cash ($3,110.8 million) + short-term investments ($1,533.9 million) − long-term debt ($598.8 million); Cityfort calculation from the Q3 FY2026 10-Q. It leaves out long-term investments and leases.
- The debt is a 4.3% note due Jun 15, 2028. A $750 million credit line maturing Jul 15, 2027 was undrawn at Dec 31, 2025.
- Edwards also carried a $580.3 million non-current liability for uncertain tax positions at Sep 30, 2026.

## Who owns Edwards Lifesciences? (as of Jan 31, 2026)

Edwards has one class of common stock with one vote per share. Its 15 directors and executive officers held 1,805,393 shares at Jan 31, 2026, or 0.31%, as the 2026 proxy states. That count includes options and units they could acquire within 60 days. The rows have different dates and are not added together. [S13, S1]

- Officers and directors (as a group), shares: 0.31%

| Class | Shares (millions) | Votes per share | % of shares | % of votes | Traded | Sources |
| --- | --- | --- | --- | --- | --- | --- |
| Common stock (575.0 million shares at Oct 31, 2026 (Q3 FY2026 10-Q cover), down from 580.8 million at Jan 31, 2026 (FY2025 10-K cover). No preferred shares are outstanding.) | 575 | 1 | — | — | Yes | S1, S4 |

Holders of 5% or more (each row shows the date of its own filing):

| Holder | Shares | Votes | As of | Note | Sources |
| --- | --- | --- | --- | --- | --- |
| The Vanguard Group | 11.72% | — | Jan 30, 2025 | 69,131,602 shares, as listed in the 2026 proxy from a Schedule 13G/A filed Jan 30, 2025. | S13 |
| BlackRock, Inc. | 7.5% | — | Oct 17, 2025 | 44,267,376 shares, as listed in the 2026 proxy from a Schedule 13G filed Oct 17, 2025. | S13 |

## What could go wrong

### Most sales come from one product family

TAVR valves brought in $4.49 billion, 74% of FY2025 net sales. TAVR grew 8.0% in Q3 FY2026, against 11.1% for the first nine months. [S4, S14, S1]

What to watch: TAVR sales growth each quarter.

### Large rivals in every product line

The FY2025 10-K names Medtronic and Abbott as main competitors in TAVR and surgical valves, and Abbott in mitral and tricuspid devices. It adds that many companies are developing devices in those fields. [S4]

What to watch: Rival approvals and Edwards’ comments on its US TAVR position in earnings releases.

### Patent and litigation costs

Patent agreement and litigation expenses were $325.4 million in FY2025, up from $40.4 million in FY2024. In Jan 2026 Cardiovalve and MTH IP sued, alleging that the PASCAL system infringes a patent and seeking damages and an injunction. [S4, S1]

What to watch: The “IP agreement and certain litigation expenses” line each quarter.

### Tax disputes

The IRS seeks $269.3 million of extra tax for 2015 to 2017, which Edwards contests. The nine-month FY2026 effective tax rate was 31.2%, including a $174.4 million item. [S4, S1]

What to watch: Uncertain tax position liabilities in each 10-Q ($580.3 million non-current at Sep 30, 2026).

### Write-downs on deals and projects

Edwards booked a $146.9 million impairment loss in FY2025 and a $163.6 million loss on a convertible note and warrant in 2026. Q3 FY2026 added a $220.2 million impairment tied to a discontinued research project. [S4, S1]

What to watch: Impairment lines in the statement of operations.

### Tariffs on imported devices

The FY2025 10-K lists a US Commerce Department Section 232 investigation into imports of medical equipment as a risk. Edwards makes products in Singapore, Costa Rica and Ireland as well as the US. [S4]

What to watch: The outcome of the Section 232 investigation and any tariff cost in gross margin.

### Single-source materials

Edwards buys some supplies from single sources and gets bovine tissue only from the United States and Australia, according to the FY2025 10-K. [S4]

What to watch: Supply problems or product holds mentioned in 10-Q filings.

## What to watch

Next: Q4 FY2026 results, Date not announced yet.

- **TAVR growth against the raised 2026 range:** TAVR sales grew 8.0% in Q3 FY2026. On Nov 4, 2026 Edwards said it expects 2026 TAVR growth of 9.0% to 9.5% at constant currency.
- **TMTT sales against the 2026 range:** TMTT sales were $583.2 million in the first nine months of 2026. Edwards’ Nov 4, 2026 range for the full year is $780 million to $790 million.
- **Final hearing on the Patel class action settlement:** The court preliminarily approved a proposed settlement on Aug 3, 2026, and the final hearing is set for Dec 16, 2026, according to the Q3 FY2026 10-Q.

## Sources

- S1: Form 10-Q for Q3 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980026000054/0001099800-26-000054-index.htm (published Nov 4, 2026)
- S2: Form 10-Q for Q2 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980026000043/0001099800-26-000043-index.htm (published Aug 4, 2026)
- S3: Form 10-Q for Q1 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980026000026/0001099800-26-000026-index.htm (published May 6, 2026)
- S4: Form 10-K for FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980026000009/0001099800-26-000009-index.htm (published Feb 25, 2026)
- S5: Form 10-Q for Q3 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980025000062/0001099800-25-000062-index.htm (published Nov 5, 2025)
- S6: Form 10-Q for Q2 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980025000048/0001099800-25-000048-index.htm (published Aug 6, 2025)
- S7: Form 10-Q for Q1 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980025000023/0001099800-25-000023-index.htm (published May 6, 2025)
- S8: Form 10-K for FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980025000005/0001099800-25-000005-index.htm (published Feb 28, 2025)
- S9: Form 10-Q for Q3 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980024000086/0001099800-24-000086-index.htm (published Nov 6, 2024)
- S10: Form 10-Q for Q2 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980024000078/0001099800-24-000078-index.htm (published Jul 31, 2024)
- S11: Form 10-Q for Q1 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980024000039/0001099800-24-000039-index.htm (published Apr 29, 2024)
- S12: Form 10-K for FY2023. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980024000004/0001099800-24-000004-index.htm (published Feb 12, 2024)
- S13: 2026 proxy statement (DEF 14A). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980026000015/ew-20260326.htm (published Mar 26, 2026)
- S14: Q3 FY2026 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980026000053/ex-991q32026.htm (published Nov 4, 2026)
- S15: Q2 FY2026 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980026000038/ex-991q22026.htm (published Jul 23, 2026)
- S16: Q1 FY2026 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980026000021/ex-991q12026.htm (published Apr 23, 2026)
- S17: Q4 FY2025 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980026000006/ex-991q42025.htm (published Feb 10, 2026)
- S18: Q3 FY2025 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980025000059/ex-991q32025.htm (published Oct 30, 2025)
- S19: Q2 FY2025 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980025000037/ex-991q22025.htm (published Jul 24, 2025)
- S20: Q1 FY2025 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980025000020/ex-991q12025.htm (published Apr 23, 2025)
- S21: Q4 FY2024 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980025000003/ex-991q42024.htm (published Feb 11, 2025)
- S22: 8-K filed Aug 28, 2026 (Item 5.02, officer departure). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980026000048/ew-20260825.htm (published Aug 28, 2026)
- S23: 8-K filed May 4, 2026 (Item 5.02, new CFO). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980026000023/ew-20260502.htm (published May 4, 2026)
- S24: 8-K filed Aug 19, 2025 (Item 8.01, accelerated share repurchase). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980025000056/ew-20250819.htm (published Aug 19, 2025)
- S25: Form 10-K for FY2022. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1099800/000109980023000005/ew-20221231.htm (published Feb 13, 2023)
